59,578 Shares in Theratechnologies Inc. (NASDAQ:THTX) Purchased by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. bought a new position in Theratechnologies Inc. (NASDAQ:THTX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 59,578 shares of the company’s stock, valued at approximately $108,000. Hillsdale Investment Management Inc. owned approximately 0.13% of Theratechnologies at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in Theratechnologies during the 4th quarter worth approximately $27,000. Virtu Financial LLC bought a new position in shares of Theratechnologies during the fourth quarter valued at approximately $40,000. Wealthspire Advisors LLC lifted its holdings in Theratechnologies by 39.0% during the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after buying an additional 20,000 shares in the last quarter. Harbour Investments Inc. lifted its holdings in shares of Theratechnologies by 20.0% in the 4th quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock worth $159,000 after buying an additional 14,655 shares during the period. Finally, National Bank of Canada FI lifted its position in shares of Theratechnologies by 29.4% in the 3rd quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock worth $232,000 after purchasing an additional 42,435 shares during the period.

Analyst Upgrades and Downgrades

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a research note on Friday, February 14th.

Theratechnologies Stock Performance

NASDAQ THTX opened at $1.57 on Tuesday. The firm has a market capitalization of $72.19 million, a P/E ratio of -15.70 and a beta of 1.24. The stock’s fifty day moving average is $1.65 and its two-hundred day moving average is $1.48. Theratechnologies Inc. has a fifty-two week low of $1.08 and a fifty-two week high of $2.18.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.